Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dynavax Technologies Corp. (DVAX)
NASDAQ:DVAX
Holding DVAX?
Track your performance easily
DVAX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.74 - $15.15
Previous Close$11.5
Volume602.30K
Average Volume (3M)2.23M
Market Cap
$1.50B
Enterprise Value$1.02B
Total Cash (Recent Filing)$735.61M
Total Debt (Recent Filing)$250.75M
Price to Earnings (P/E)105.2
Beta0.59
Next Earnings
Oct 31, 2024EPS Estimate
$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.11
Shares Outstanding131,044,383
10 Day Avg. Volume1,885,219
30 Day Avg. Volume2,227,801
Standard Deviation0.22
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.34
Price to Sales (P/S)5.88
Price to Cash Flow (P/CF)34.30
P/FCF Ratio32.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.09
Enterprise Value/Gross Profit5.61
Enterprise Value/Ebitda52.12
Forecast
1Y Price Target
$24.50Price Target Upside114.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Dynavax News
PremiumCompany Announcements
Kelly MacDonald Returns as CFO to Dynavax Technologies
Bulls Say, Bears Say
Bulls Say
Clinical TrialsDynavax announced that the first patient has been dosed in its Phase 1/2 study of its shingles vaccine candidate Z-1018, which could potentially have a better safety profile compared to the currently marketed vaccine Shingrix.
Market Share GrowthHeplisav-B market share in retail at the end of 2Q24 was approximately 59%, compared to approximately 55% at the end of 1Q24 and approximately 45% at the end of 2Q23.
Revenue GuidanceDynavax reaffirmed FY24 Heplisav-B net product revenue guidance of between $265M-$280M.
Bears Say
Pipeline ConcernsAbsence of near-term derisking catalysts for the company's early-stage pipeline, which is likely to remain in a holding pattern for the foreseeable future.
Regulatory IssuesThe FDA issued a Complete Response Letter (CRL) for Heplisav's sBLA in adults on hemodialysis citing insufficient data due to the destruction of records by a trial site.
Sales PerformanceDVAX reported its 2Q24 results with sales of its Heplisav-B vaccine coming in below Visible Alpha Consensus Data.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DVAX FAQ
What was Dynavax Technologies Corp.’s price range in the past 12 months?
Dynavax Technologies Corp. lowest stock price was $9.74 and its highest was $15.15 in the past 12 months.
What is Dynavax Technologies Corp.’s market cap?
Currently, no data Available
When is Dynavax Technologies Corp.’s upcoming earnings report date?
Dynavax Technologies Corp.’s upcoming earnings report date is Oct 31, 2024 which is in 41 days.
How were Dynavax Technologies Corp.’s earnings last quarter?
Dynavax Technologies Corp. released its earnings results on Aug 06, 2024. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.065 by $0.015.
Is Dynavax Technologies Corp. overvalued?
According to Wall Street analysts Dynavax Technologies Corp.’s price is currently Undervalued.
Does Dynavax Technologies Corp. pay dividends?
Dynavax Technologies Corp. does not currently pay dividends.
What is Dynavax Technologies Corp.’s EPS estimate?
Dynavax Technologies Corp.’s EPS estimate is $0.12.
How many shares outstanding does Dynavax Technologies Corp. have?
Dynavax Technologies Corp. has 131,044,390 shares outstanding.
What happened to Dynavax Technologies Corp.’s price movement after its last earnings report?
Dynavax Technologies Corp. reported an EPS of $0.08 in its last earnings report, beating expectations of $0.065. Following the earnings report the stock price went up 6.965%.
Which hedge fund is a major shareholder of Dynavax Technologies Corp.?
Among the largest hedge funds holding Dynavax Technologies Corp.’s share is Fisher Asset Management LLC. It holds Dynavax Technologies Corp.’s shares valued at 16M.
---
Dynavax Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.50 (114.07% Upside)
$24.50 (114.07% Upside)
Blogger Sentiment
Bullish
DVAX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 419.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.24%
12-Months-Change
Fundamentals
Return on Equity
2.82%
Trailing 12-Months
Asset Growth
8.53%
Trailing 12-Months
Company Description
Dynavax Technologies Corp.
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.
---
DVAX Company Deck
---
DVAX Earnings Call
Q2 2024
0:00 / 0:00
---
DVAX Stock 12 Month Forecast
Average Price Target
$24.50
▲(114.07% Upside)
Technical Analysis
Best Analysts Covering DVAX
1 Year
1 Year Success Rate
14/27 ratings generated profit
1 Year Average Return
+2.00%
reiterated a buy rating last month
Copying Edward White's trades and holding each position for 1 Year would result in 51.85% of your transactions generating a profit, with an average return of +2.00% per trade.
---